Haemonetics (HAE) has disclosed a new risk, in the Environmental / Social category.
Haemonetics faces heightened business risks due to climate change and the associated regulatory measures. The unpredictability of long-term climate effects threatens their operational efficiency and supply chain, particularly in the sourcing of raw materials and essential natural resources like water. Moreover, stringent climate-related legislation could impose greater compliance costs and disrupt product manufacturing and distribution. Failing to adapt to evolving customer preferences related to climate change could also lead to a loss of market share, adversely impacting Haemonetics’ financial stability and operational results.
Overall, Wall Street has a Strong Buy consensus rating on HAE stock based on 3 Buys and 1 Hold.
To learn more about Haemonetics’ risk factors, click here.
